Last reviewed 2026-06-02 · How we verify

ALMAGATE

Phase 2 active Small molecule

ALMAGATE is a almagate drug. It is currently in Phase 2 development.

Almagate works by binding to and removing excess phosphate ions from the body.

Almagate is a small molecule drug in the almagate class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are not specified. Almagate is used to treat unknown indications, and its commercial status, including patent status and generic availability, is unclear. The safety profile of almagate is also unknown. Further research is needed to fully understand this medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ALMAGATE
Drug class	almagate
Modality	Small molecule
Therapeutic area	Nephrology
Phase	Phase 2

Mechanism of action

Think of it like a sponge that soaks up extra phosphate in the body, helping to balance levels and prevent problems. This can be especially important for people with conditions that cause phosphate buildup, like kidney disease. By removing excess phosphate, almagate can help reduce symptoms and improve quality of life.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ALMAGATE CI brief — competitive landscape report
ALMAGATE updates RSS · CI watch RSS

Frequently asked questions about ALMAGATE

What is ALMAGATE?

ALMAGATE is a almagate drug.

How does ALMAGATE work?

Almagate works by binding to and removing excess phosphate ions from the body.

What drug class is ALMAGATE in?

ALMAGATE belongs to the almagate class. See all almagate drugs at /class/almagate.

What development phase is ALMAGATE in?

ALMAGATE is in Phase 2.

Drug class: All almagate drugs
Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing